| 764088 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
219 CD47 and phosphatidylserine contribute to the interaction between antigen presenting cells and the allogeneic cell-based relapse vaccine DCP-001 |
2021-11-01 |
10.1136/jitc-2021-sitc2021.219 |
Zuo Haoxiao, Singh Satwinder Kaur, Lierop Marie-José Van, Kaspers Jorn, Bos Remco, Kamermans Alwin, Vries Helga E de, Gruijl Tanja de, Kruisbeek Ada, Manting Erik, Singh Satwinder Kaur |
| 764087 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
211 SQZ™ eAPCs generated from PBMCs by delivery of multiple mRNAs encoding for antigens, costimulatory proteins, and engineered cytokines |
2021-11-01 |
10.1136/jitc-2021-sitc2021.211 |
Maloney Michael, Ozay Emrah Ilker, Merino Amy, Silva Andrea, Martin Amber, Manja Sanjana, Upadhyay Madhav, Trumpfheller Christine, Umana Pablo, Sharei Armon, Bernstein Howard, Loughhead Scott |
| 764086 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
209 Genetically engineered myeloid cells (GEMys) as a platform to enhance antitumor immunity |
2021-11-01 |
10.1136/jitc-2021-sitc2021.209 |
Kaczanowska Sabina, Beury Daniel, Qin Haiying, Kaplan Rosandra |
| 764085 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
202 In vivo and in vitro characterization of AIM ACT, a novel nanoparticle-based technology, expanded MART-1 specific T cells |
2021-11-01 |
10.1136/jitc-2021-sitc2021.202 |
Wang Ruipeng, Suarez Lauren, Lu Emily, Kunwar Pratima, Dembrow Daniel, Kim Sojung, Oelke Mathias |
| 764084 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
201 BNT221, an autologous neoantigen-specific T-cell product for adoptive cell therapy of metastatic ovarian cancer |
2021-11-01 |
10.1136/jitc-2021-sitc2021.201 |
Arieta Christina, Velez Diana, Hannes Susan, Meda Shirisha, McCarthy Brian, Lenkala Divya, Harjanto Dewi, Suri Prerna, Kohler Jessica, McGee Jonathan, Kallin Daniel, Turcott Paul, Nijenhuis Cynthia, Rohaan Maarje, Sonke Gabe, Haanen John, DeMario Mark, Gaynor Richard, Buuren Marit Van |
| 764083 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
186 Development of KSQ-001, an engineered TIL (eTIL) therapy for solid tumors through CRISPR/Cas9-mediated editing of SOCS1 |
2021-11-01 |
10.1136/jitc-2021-sitc2021.186 |
Wong Karrie, Lin Sharon, Wrocklage Christopher, Sofjan Katri, Williams Leila, Brady Mallory, Colletti Nicholas, Tubo Noah, Gannon Hugh, LaMothe Robert, Xu Tianlei, VandenBerg Tracy, Shenker Sol, Dugopolski Caroline, Stegmeier Frank, Cadzow Louise, Schlabach Michael, Benson Micah |
| 764082 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
179 CD8+CD69+ Expanded Tumor Infiltrating Lymphocytes from Soft Tissue Sarcoma Have Increased Tumor-Specific Functional Capacity |
2021-11-01 |
10.1136/jitc-2021-sitc2021.179 |
Hensel Jonathan, Alfaro Alejandro, Rau Mary, Perez-Villarroel Patricio, Sannasardo Zachary, Pilon-Thomas Shari, Mullinax John |
| 764081 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
171 Targeting the Immunomodulatory roles of T-cell immunoglobulin– and mucin domain–containing (TIM)–3 on natural killer cells in glioblastoma |
2021-11-01 |
10.1136/jitc-2021-sitc2021.171 |
Dao Tram, Matosevic Sandro |
| 764080 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
166 Genetically engineered tumor-infiltrating lymphocytes (cytoTIL15) exhibit IL-2-independent persistence and anti-tumor efficacy against melanoma in vivo |
2021-11-01 |
10.1136/jitc-2021-sitc2021.166 |
Burga Rachel, Khattar Mithun, Lajoie Scott, Pedro Kyle, Foley Colleen, Ocando Alonso Villasmil, Tremblay Jack, Primack Benjamin, Langley Meghan, Thornton Dan, Tam Stanley, Brideau Emily, Ross Theresa, Wilmes Gwen, Saha Sunandan, Helmlinger Gabriel, Tchaicha Jeremy, Sethi Dhruv, Ols Michelle, Vanasse Gary, Subramanian Shyam, Meulen Jan ter |
| 764079 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
879 A promising cancer immunotherapy target: novel fully human agonist antibodies against the human T-cell costimulatory receptor CD27 |
2021-11-01 |
10.1136/jitc-2021-sitc2021.879 |
Guillaudeux Thierry, Ovechkina Yulia, Sridhar Shaarwari, Jurchen David, Peckham David, Frazier Emily, Tarcha Eric, Iadonato Shawn |
